Campylobacter jejuni is a leading cause of human foodborne illness, and pet dogs can be a source of infection. Despite recognition of this zoonotic potential, tests for detection of C. jejuni are not performed routinely in dogs. We compared bacterial culture and molecular methods for the detection of C. jejuni directly from canine feces and from Bolton enrichment broth inoculated with feces in a multi-laboratory randomized-method test. Although culture offers the advantage of collection of isolates for further epidemiologic study, real-time PCR (rtPCR) to detect cpn60 from DNA isolated directly from canine feces was more sensitive than culture and more accurate than rtPCR using DNA isolated from enrichment cultures. The limit of detection for our cpn60 rtPCR was 320 cfu/g.
10 June 2026 in Journal of Veterinary Diagnostic Investigation
A 2016–2018 outbreak in the United States demonstrated the importance of pet dogs as a source of Campylobacter jejuni . Canine feces are not tested routinely for C. jejuni . We previously compared culture-based and molecular methods for detection of C. jejuni and found that a cpn60 real-time PCR (rtPCR) assay using DNA isolated directly from canine feces was more reliable than culture, with a limit of detection (LOD) of 320 cfu/g. Later, during an outbreak investigation, a gyrA rtPCR assay had a LOD of 40 cfu/g. In our inter-laboratory comparison exercise, 27 analysts at 19 laboratories successfully detected C. jejuni in canine feces using the gyrA rtPCR. Samples inoculated with 45,600 cfu/g were correctly identified as positive by 100% of analysts. Samples inoculated with 4,700, 460, or 200 cfu/g were correctly identified by 96%, 77%, and 40% of analysts, respectively. The addition of C. jejuni gyrA rtPCR to previous methods allows laboratories to rapidly identify C. jejuni -positive canine fecal samples at a lower LOD. Isolation of DNA directly from feces rather than from enrichment broth offers the advantage of fewer opportunities for cross-contamination during testing and decreased time between specimen collection and test completion. The updated method, with the addition of the gyrA rtPCR, offers increased sensitivity and will ultimately improve overall detection of C. jejuni in canine feces at veterinary diagnostic laboratories, further supporting canine and public health.
The coronavirus disease 2019 (COVID-19) pandemic presents a continued public health challenge across the world. Veterinary diagnostic laboratories in the U.S. use real-time reverse transcriptase PCR (RT-PCR) for animal testing, and many are certified for testing human samples, so ensuring laboratories have sensitive and specific SARS-CoV-2 testing methods is a critical component of the pandemic response. In 2020, the FDA Veterinary Laboratory Investigation and Response Network (Vet-LIRN) led the first round of an Inter-Laboratory Comparison (ILC) Exercise to help laboratories evaluate their existing real-time RT-PCR methods for detecting SARS-CoV-2. The ILC1 results indicated that all participating laboratories were able to detect the viral RNA spiked in buffer and PrimeStore molecular transport medium (MTM). The current ILC (ILC2) aimed to extend ILC1 by evaluating analytical sensitivity and specificity of the methods used by participating laboratories to detect three SARS-CoV-2 variants (B.1, B.1.1.7 (Alpha) and B.1.351 (Beta)). ILC2 samples were prepared with RNA at levels between 10 to 10,000 copies per 50 μL MTM. Fifty-seven sets of results from 45 laboratories were qualitatively and quantitatively analyzed according to the principles of ISO 16140-2:2016. The results showed that over 95% of analysts detected the SARS-CoV-2 RNA in MTM at 500 copies or higher for all three variants. In addition, 81% and 92% of the analysts achieved a Level of Detection (LOD95 eff. vol. ) below 20 copies in the assays with nucleocapsid markers N1 and N2, respectively. The analytical specificity of the evaluated methods was over 99%. The study allowed participating laboratories to assess their current method performance, identify possible limitations, and recognize method strengths as part of a continuous learning environment to support the critical need for reliable diagnosis of COVID-19 in potentially infected animals and humans.
25 March 2026 in Journal of Veterinary Diagnostic Investigation
A multi-state outbreak of equine botulism occurred between December 2022 and March 2023 in the United States. Follow-up and testing were performed on 42 horses, including 24 that died or were euthanized in the outbreak that affected ~98 horses. Affected horses had all been exposed to the same commercial feed. Clinical signs included progressive muscle weakness and tremors, recumbency, and colic. No significant gross or microscopic abnormalities were observed on autopsy. Feces and gastrointestinal content were tested for various infectious agents, including botulinum toxin; fecal samples from 2 horses tested positive for botulinum neurotoxin (BoNT) type C using the mouse bioassay (MBA). Feed samples, as well as mammalian tissue found within the feed, were collected and tested; 2 samples were positive for BoNT type C by MBA. Based on these results, a diagnosis of botulism was established, and the contaminated feed was identified as the source of exposure. We highlight the diagnostic challenges associated with equine botulism and the importance of regulatory agencies and interagency collaboration during outbreaks.
Background: Since the beginning of the COVID-19 pandemic veterinary diagnostic laboratories have tested diagnostic samples for SARS-CoV-2 not only in animals, but in over five million human samples. An evaluation of the performance of those laboratories is needed using blinded test samples to ensure that laboratories report reliable data to the public. This interlaboratory comparison exercise (ILC3) builds on two prior exercises to assess whether veterinary diagnostic laboratories can detect Delta and Omicron variants spiked in canine nasal matrix or viral transport medium. Methods: Inactivated Delta variant at levels of 25 to 1,000 copies per 50 μL of nasal matrix were prepared for participants by the ILC organizer, an independent laboratory, for blinded analysis. Omicron variant at 1,000 copies per 50 μL of transport medium was also included. Feline infectious peritonitis virus (FIPV) RNA was used as a confounder for specificity assessment. A total of 14 test samples were prepared for each participant. Participants used their routine diagnostic procedures for RNA extraction and real-time RT-PCR. Results were analyzed according to International Organization for Standardization (ISO) 16140 - 2:2016. Results: The overall results showed 93% detection for Delta and 97% for Omicron at 1,000 copies per 50 μL (22-200 copies per reaction). The overall specificity was 97% for blank samples and 100% for blank samples with FIPV. No differences in Ct values were significant for samples with the same virus levels between N1 and N2 markers, nor between the two variants. Conclusions: The results indicated that all ILC3 participants were able to detect both Delta and Omicron variants. The canine nasal matrix did not significantly affect SARS-CoV-2 detection. Impact Statement: Ensuring accurate detection methods for SARS-CoV-2 is critical as veterinary diagnostic labs are testing both human and animal samples. This exercise used blinded test samples and provided high confidence in the sensitivity of methods in twenty-nine laboratories for detection of SARS-CoV-2 variants while addressing the impact of sample matrix. Importantly, the results indicated that variants and matrix do not impact detection results. Additionally, this article examined decision-making criteria for Ct cut-off values from different laboratories and encouraged them to review and potentially reassess their criteria to improve future performance. This knowledge will lead to higher confidence in laboratory detection of current and new SARS-CoV-2 variants and aid in establishing reasonable cut-off parameters for these diagnostics tests.
3 July 2026 in Journal of Veterinary Diagnostic Investigation
We evaluated a semi-automated method for DNA extraction, expanded to herbivore feces a gyrA PCR method for the detection of Campylobacter jejuni in canine feces, added an internal positive control (IPC) DNA to specimens before DNA extraction, and multiplexed the gyrA PCR assay with the IPC assay. The addition of IPC DNA and multiplexing of the IPC assay did not affect the performance of the gyrA PCR assay. The method was repeatable with no significant difference in results across 6 d (F = 0.715; p = 0.614 with R2 = 0.818). In a single-laboratory randomized method test evaluating detection in bovine feces, sensitivity was 96.1%, specificity was 100%, and accuracy was 94.1%. In a multi-laboratory randomized method test (M-RMT) in bovine feces, agreement was 90% between laboratories on test results with κ = 0.80 (95% CI [0.64, 0.96]). Comparison of manual DNA extraction kits with a semi-automated extraction method in canine feces found 88.9% agreement, with κ = 0.78 (95% CI [0.64, 0.92]). In a second M-RMT in canine feces, accuracy was 78% with 90% agreement between the laboratories and κ = 0.80 (95% CI [0.64, 0.96]), even though inoculation of the intended fractional level was lower than intended at 45 cfu/g feces. Overall, the gyrA PCR assay was extended to an additional matrix, the inclusion of an IPC DNA and assay was successful, and the gyrA PCR assay for the detection of Campylobacter jejuni provided repeatable results in multiple laboratories.